

Helmut Klocker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10560817/publications.pdf>

Version: 2024-02-01

83
papers

6,126
citations

100601

38
h-index

129628

63
g-index

84
all docs

84
docs citations

84
times ranked

6491
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer. <i>Oncogene</i> , 2021, 40, 3087-3100.	2.6	18
2	Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature. <i>International Journal of Medical Sciences</i> , 2019, 16, 115-124.	1.1	5
3	miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer. <i>Molecular Endocrinology</i> , 2015, 29, 1037-1054.	3.7	69
4	Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis. <i>Oncotarget</i> , 2014, 5, 2723-2735.	0.8	67
5	PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. <i>Oncotarget</i> , 2014, 5, 12043-12056.	0.8	29
6	Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205. <i>American Journal of Pathology</i> , 2012, 181, 2188-2201.	1.9	225
7	PIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21. <i>American Journal of Pathology</i> , 2012, 180, 2097-2107.	1.9	72
8	Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. <i>International Journal of Public Health</i> , 2012, 57, 57-62.	1.0	39
9	Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection. <i>European Urology</i> , 2010, 57, 921-927.	0.9	223
10	Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. <i>International Journal of Cancer</i> , 2010, 126, 775-789.	2.3	20
11	Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 18437-18442.	3.3	378
12	Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. <i>BJU International</i> , 2008, 101, 809-816.	1.3	120
13	A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. <i>Bioinformatics</i> , 2008, 24, 2908-2914.	1.8	67
14	Androgen Receptor Function in Prostate Cancer Progression. , 2007, , 87-105.		4
15	Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2006, 102, 103-113.	1.2	92
16	Reduction of Prostate Cancer Mortality in Tyrol, Austria, after Introduction of Prostate-specific Antigen Testing. <i>American Journal of Epidemiology</i> , 2006, 164, 376-384.	1.6	67
17	Ability of PSA-positive circulating macrophages to detect prostate cancer. <i>Prostate</i> , 2005, 62, 290-298.	1.2	11
18	Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk. <i>Prostate</i> , 2005, 64, 240-245.	1.2	52

#	ARTICLE	IF	CITATIONS
19	Novel Experimental Therapeutic Approaches for Prostate Cancer. EAU Update Series, 2005, 3, 227-239.	0.5	1
20	Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2005, 96, 251-258.	1.2	127
21	Targeting the androgen receptor in hormone-refractory prostate cancer ? new concepts. Future Oncology, 2005, 1, 93-101.	1.1	19
22	Androgen Receptor Regulation by Physiological Concentrations of the Isoflavonoid Genistein in Androgen-Dependent LNCaP Cells Is Mediated by Estrogen Receptor β . European Urology, 2004, 45, 245-251.	0.9	107
23	SERUM PRO-PROSTATE SPECIFIC ANTIGEN PREFERENTIALLY DETECTS AGGRESSIVE PROSTATE CANCERS IN MEN WITH 2 TO 4 NG/ML PROSTATE SPECIFIC ANTIGEN. Journal of Urology, 2004, 171, 2239-2244.	0.2	149
24	Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells. Molecular Carcinogenesis, 2003, 37, 181-191.	1.3	27
25	Androgen Receptors in Prostate Cancer. Journal of Urology, 2003, 170, 1363-1369.	0.2	87
26	Serum Pro Prostate Specific Antigen Improves Cancer Detection Compared to Free and Complexed Prostate Specific Antigen in Men With Prostate Specific Antigen 2 to 4 Ng/ML. Journal of Urology, 2003, 170, 2181-2185.	0.2	151
27	Impact of age on complexed PSA levels in men with total PSA levels of up to 20 ng/mL. Urology, 2003, 62, 840-844.	0.5	13
28	The Cochaperone Bag-1L Enhances Androgen Receptor Action via Interaction with the NH ₂ -Terminal Region of the Receptor. Molecular and Cellular Biology, 2003, 23, 7189-7197.	1.1	72
29	Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Therapy, 2002, 9, 117-125.	2.2	105
30	Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology, 2001, 58, 417-424.	0.5	280
31	Androgen Receptor Mutations in Carcinoma of the Prostate. Molecular Diagnosis and Therapy, 2001, 1, 241-249.	3.3	43
32	Human rhabdosphincter cell culture: A model for videomicroscopy of cell contractions. Prostate, 2001, 47, 189-193.	1.2	7
33	Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. Prostate, 2001, 49, 145-154.	1.2	35
34	Molecular Biology of the Androgen Receptor: From Molecular Understanding to the Clinic. European Urology, 2001, 40, 241-251.	0.9	92
35	Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. Journal of Pathology, 2000, 191, 239-244.	2.1	153
36	Expression and function of androgen receptor in carcinoma of the prostate. Microscopy Research and Technique, 2000, 51, 447-455.	1.2	32

#	ARTICLE	IF	CITATIONS
37	Effects of α 1-adrenoceptor antagonists on cultured prostatic smooth muscle cells. <i>Prostate</i> , 2000, 45, 34-41.	1.2	16
38	Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models. <i>Prostate</i> , 2000, 45, 124-131.	1.2	61
39	Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. <i>Cancer Gene Therapy</i> , 2000, 7, 997-1007.	2.2	151
40	An in vitro model for videoimaging of human bladder smooth muscle cell contractions. <i>Urological Research</i> , 2000, 28, 250-253.	1.5	7
41	Selective culture conditions for different types of primary human bladder cells. <i>World Journal of Urology</i> , 2000, 18, 371-375.	1.2	6
42	Rapid signalling by androgen receptor in prostate cancer cells. <i>Oncogene</i> , 1999, 18, 6322-6329.	2.6	238
43	Modulation of the differentiation status of cultured prostatic smooth muscle cells by an α 1-adrenergic receptor antagonist. , 1999, 39, 226-233.		48
44	CELLULAR AND HUMORAL IMMUNE RESPONSES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AFTER VACCINATION WITH ANTIGEN PULSED DENDRITIC CELLS. <i>Journal of Urology</i> , 1999, 161, 777-782.	0.2	229
45	CELLULAR AND HUMORAL IMMUNE RESPONSES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AFTER VACCINATION WITH ANTIGEN PULSED DENDRITIC CELLS. <i>Journal of Urology</i> , 1999, , 777-782.	0.2	14
46	Presence of chromogranins and regulation of their synthesis and processing in a neuroendocrine prostate tumor cell line. <i>Prostate</i> , 1998, 36, 80-87.	1.2	20
47	Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. , 1998, 35, 63-70.		109
48	Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma. , 1998, 36, 162-167.		11
49	Videoimaging of prostatic stromal-cell contraction: An in vitro model for studying drug effects. , 1998, 37, 209-214.		25
50	Recent developments in molecular action of antihormones. <i>Journal of Molecular Medicine</i> , 1998, 76, 512-524.	1.7	20
51	ACTIVATION OF HUMAN DENDRITIC CELLS BY BACILLUS CALMETTE-GUERIN. <i>Journal of Urology</i> , 1998, 159, 1488-1492.	0.2	26
52	Differential Deactivation of Human Dendritic Cells by Endotoxin Desensitization: Role of Tumor Necrosis Factor- α and Prostaglandin E2. <i>Blood</i> , 1998, 91, 3112-3117.	0.6	65
53	Videoimaging of prostatic stromal-cell contraction: An in vitro model for studying drug effects. , 1998, 37, 209.		1
54	Differential Deactivation of Human Dendritic Cells by Endotoxin Desensitization: Role of Tumor Necrosis Factor- α and Prostaglandin E2. <i>Blood</i> , 1998, 91, 3112-3117.	0.6	5

#	ARTICLE	IF	CITATIONS
55	ANDROGEN RECEPTOR POINT MUTATIONS AS THE UNDERLYING MOLECULAR DEFECT IN 2 PATIENTS WITH ANDROGEN INSENSITIVITY SYNDROME. <i>Journal of Urology</i> , 1997, 158, 1553-1556.	0.2	26
56	Androgen Receptor Gene Mutations in Prostate Cancer. <i>Drugs and Aging</i> , 1997, 10, 50-58.	1.3	41
57	Prostaglandin E2 and Tumor Necrosis Factor α Cooperate to Activate Human Dendritic Cells: Synergistic Activation of Interleukin 12 Production. <i>Journal of Experimental Medicine</i> , 1997, 186, 1603-1608.	4.2	251
58	A reliable system for the culture of human prostatic cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1997, 33, 742-744.	0.7	18
59	Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. , 1997, 182, 356-361.		57
60	Human prostatic smooth muscle cells in culture: Estradiol enhances expression of smooth muscle cell-specific markers. , 1997, 30, 117-129.		77
61	Frequency and clinical significance of transition zone cancer in prostate cancer screening. , 1997, 30, 130-135.		55
62	Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. , 1997, 31, 223-233.		87
63	Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. , 1997, 32, 106-114.		66
64	Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells. , 1997, 70, 128-134.		112
65	Frequency and clinical significance of transition zone cancer in prostate cancer screening. , 1997, 30, 130.		2
66	Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. , 1997, 31, 223.		2
67	Usefulness of the ratio free/total prostatespecific antigen in addition to total PSA levels in prostate cancer screening. <i>Urology</i> , 1996, 48, 62-66.	0.5	47
68	Human renal-cell carcinoma tissue contains dendritic cells. <i>International Journal of Cancer</i> , 1996, 68, 1-7.	2.3	135
69	Transforming Growth Factors-beta 1 and beta 2 in Serum and Urine from Patients with Bladder Carcinoma. <i>Journal of Urology</i> , 1996, 156, 953-957.	0.2	79
70	Androgen receptor status of lymph node metastases from prostate cancer. , 1996, 28, 129-135.		125
71	Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. , 1996, 28, 172-181.		25
72	Regulation of prostatic growth and function by peptide growth factors. , 1996, 28, 392-405.		269

#	ARTICLE	IF	CITATIONS
73	Evaluation and comparison of two new prostate carcinoma markers: Free-prostate specific antigen and prostate specific membrane antigen. , 1996, 78, 809-818.		51
74	Androgen Receptor-Ets Protein Interaction Is a Novel Mechanism for Steroid Hormone-mediated Down-modulation of Matrix Metalloproteinase Expression. Journal of Biological Chemistry, 1996, 271, 23907-23913.	1.6	147
75	Androgen receptor status of lymph node metastases from prostate cancer. , 1996, 28, 129.		3
76	Human renal-cell carcinoma tissue contains dendritic cells. , 1996, 68, 1.		1
77	Tumor-infiltrating T lymphocytes from renal-cell carcinoma express B7-1 (CD80): T-Cell expansion by T-T cell co-stimulation. International Journal of Cancer, 1995, 62, 559-564.	2.3	17
78	Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. International Journal of Cancer, 1995, 63, 544-550.	2.3	78
79	Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients. International Journal of Cancer, 1995, 63, 627-632.	2.3	47
80	In Vivo LDL Receptor and HMG-CoA Reductase Regulation in Human Lymphocytes and Its Alterations During Aging. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 872-878.	1.1	23
81	Androgen receptor alterations in prostatic carcinoma. Prostate, 1994, 25, 266-273.	1.2	53
82	DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate, 1993, 22, 11-22.	1.2	118
83	Decreased Level of Thymidine in the Serum of Obese Strain (OS) Chickens with Spontaneous Autoimmune Thyroiditis. Immunological Investigations, 1988, 17, 243-256.	1.0	4